Previous Close | 6.33 |
Open | 6.13 |
Bid | 6.01 x 900 |
Ask | 6.22 x 2200 |
Day's Range | 6.05 - 6.13 |
52 Week Range | 3.51 - 8.10 |
Volume | |
Avg. Volume | 16,320 |
Market Cap | 150.601M |
Beta (5Y Monthly) | 0.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.69 |
Earnings Date | Sep 07, 2022 - Sep 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.87 |
Subscribe to Yahoo Finance Plus to view Fair Value for IPA
VICTORIA, British Columbia, July 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022.
VICTORIA, British Columbia, July 26, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
VICTORIA, British Columbia, July 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, reports the critical third-party findings of two IND-enabling pre-clinical safety studies, de-risking the clinical development of the Company’s PolyTope® TATX-03 antibody cocktail and its potential to prevent and treat COVID-19. A summary of the positive findings indicates that, through ex vivo screenings, n